Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam Tosilate is a new short-acting benzodiazepines used in sedation. It has the advantages of rapid metabolism, quick recovery without injection pain. This study aims to compared with Midazolam, study whether Remimazolam Tosilate can achieve the same sedation effect with lower side effects on sedation maintenance period, During the recovery period of anesthesia, can Remimazolam Tosilatebe more stable and rapid.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University
• Treatments: Fentanyl; Flurbiprofen; Midazolam

Criteria

Inclusion Criteria:

1. Age 18-60

2. BMI in 18-30Kg / m2

3. ASA classification I-II level

4. Sign informed consent

5. Patients whose outpatient treatment time less than 1 hour

6. The methods of local anesthesia including: periosteum infiltration method, periodontal ligament injection method, regional nerve block method

Exclusion Criteria:

1. Patients who are allergic to benzodiazepines, opioids, flumazenil or have contraindications

2. Long-term use of benzodiazepines

3. Long-term use of opioids

4. Participate in other clinical trials within 4 weeks

5. Women during pregnancy or breastfeeding

6. Patients who have a history of drug abuse or long-term alcohol abuse

7. Patients who suffer from mental illness or unable to cooperate with the experiment